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A rapid and systematic review of the effectiveness and cost-effectiveness of temozolomide in the treatment of recurrent
malignant glioma was commissioned by the NHS HTA Programme on behalf of NICE. The full report has been published
elsewhere. This paper summarizes the results for the effectiveness of temozolomide in people with recurrent glioblastoma
multiforme and anaplastic astrocytoma. The review was conducted using standard systematic review methodology involving a
systematic literature search, quality assessment of included studies with systematic data extraction and data synthesis. One
randomized controlled trial and four uncontrolled studies were identiﬁed for inclusion. The key results were that
temozolomide may increase progression-free survival but has no signiﬁcant impact on overall length of survival. The main
effect from temozolomide may have been in those patients who had not received any prior chemotherapy regimens, however
further randomized controlled trials are required to conﬁrm this suggestion. Temozolomide appears to produce few serious
adverse effects and may also have a positive impact on health-related quality of life. Overall the evidence-base is weak and few
strong conclusions can be drawn regarding the effectiveness of temozolomide. Large, well-designed randomized controlled
trails conducted in a wider patient population are needed.
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Temozolomide (Temodal
1) was licensed in early 1999 for the
treatment of patients with malignant glioma showing recurrence
or progression after standard therapy (The European Agency for
the Evaluation of Medicinal Products, 1999). Current treatment
options for people with recurrent high-grade glioma (such as
anaplastic astrocytoma (AA) or glioblastoma multiforme (GBM))
are limited, and life expectancy is short (Wong et al, 1999). In
the UK, approximately one-third of patients currently receive
chemotherapy, usually consisting of a single agent nitrosourea
(e.g., CCNU or BCNU) or a combination therapy such as PCV
(procarbazine, CCNU and vincristine) (Rampling, 2000). The
success of these agents is thought to be limited, leading to consid-
erable interest in newer chemotherapy agents such as
temozolomide.
Temozolomide is claimed to be more effective, easier to administer
and have fewer side-effects than its competitors. However, a lack of
consensus regarding its true effectiveness and the relative expense
of the drug has led to variations in its use across the country.
In mid-2000 the National Institute for Clinical Excellence
(NICE) was asked to advise the NHS on ‘the use of temozolomide
in brain cancer’. Our unit was commissioned by the NHS Health
Technology Assessment Programme to conduct a systematic review
to help inform the NICE decision. This paper presents the systema-
tic review of the effectiveness literature only. The full report
(available in the HTA monograph series) also presents the econom-
ic evaluation that was conducted (Dinnes et al, 2001).
The objective of this systematic review was therefore, to evaluate
temozolomide for its licensed indications, in comparison to stan-
dard alternative chemotherapy or against best standard care, in
terms of both survival and quality of life. No existing or ongoing
systematic reviews of temozolomide were identiﬁed on the
Cochrane Library prior to undertaking the review.
MATERIALS AND METHODS
Studies were included if they assessed the effectiveness of temozo-
lomide in brain cancer and were either a randomized controlled
trial (RCT) or, if non-randomized, included over 45 patients. An
extensive literature search was conducted using the generic and
trade names for temozolomide in electronic databases (Cochrane
Library, Medline, Embase, Cancerlit and Toxline) and by scanning
reference lists of all retrieved papers. The authors of included
studies were contacted to supply additional or missing data.
Study quality was assessed using a shortened version (Dinnes et
al, 2001) of a checklist developed originally for an epidemiological
review (Spitzer et al, 1990). The scale developed by Jadad et al
(1996) was used to assess RCTs.
Two reviewers independently assessed studies for inclusion,
extracted data and evaluated the quality of each included study.
Disagreements were resolved through discussion.
Because of the paucity of data, only a narrative synthesis was
undertaken. The results are summarized according to type of
malignant glioma and outcome measures assessed. For ease of
comparison all survival times initially reported in months are
reported here in weeks (using the formula: weeks=
(months630.4)/7). All results have been rounded to one decimal
point.
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Eight full reports of six studies were identiﬁed for inclusion in the
main review (Dinnes et al, 2001). Only the ﬁve studies providing
effectiveness data for temozolomide in patients with AA or GBM
are reported here (Table 1). A full list of excluded studies is avail-
able on request from the authors. Figure 1 provides an overview of
the primary search and inclusion process.
Description of included effectiveness studies
Only one RCT was identiﬁed (Yung et al, 2000). The remaining
studies were uncontrolled (Newlands et al, 1996; Bower et al,
1997; Yung et al, 1999; Brada et al, 2001).
All studies applied similar inclusion criteria (Table 1). All
included both patients who had received prior chemotherapy (as
adjuvant treatment or at ﬁrst recurrence) and patients who were
chemotherapy-naı ¨ve.
Dosage of temozolomide was the same in all studies
(200 mg m
72 day
71 for 5 days in each 28-day cycle). In patients
who had received prior chemotherapy, the initial dose was
150 mg m
72 day
71, escalating to 200 mg m
72 day
71 after the ﬁrst
cycle if haematology results were satisfactory. The RCT compared
temozolomide to procarbazine administered at a dosage of
150 mg m
72 day
71 for 28 consecutive days in each 56-day cycle.
Quality of included studies
The method of randomization used in the RCT was not reported,
leaving the potential for inadequate concealment of allocation of
participants to treatment groups, but there did not appear to be
substantial differences in baseline characteristics between the
groups (Yung et al, 2000). Temozolomide patients on average
had a shorter time from diagnosis to recurrence, but this was
not found to have affected the results. It might reasonably be
assumed that any bias introduced by a shorter time to recurrence
would lead to poorer outcomes in the temozolomide group rather
than exaggerating any potential beneﬁt.
None of the studies give any assurance that clinicians and
patients were blinded to the treatments given (and indeed this
would not be possible in an uncontrolled study). This knowledge
is likely to have affected assessments of clinical status and patients’
self-reports of quality of life.
Outcome measures
Several outcome measures are commonly reported in cancer
trials including objective response, progression-free survival
(PFS) and overall survival. Tumour response is of uncertain
usefulness as an outcome measure in gliomas (Galanis and
Buckner, 2000) and is not reported here. More important is
the assessment of survival (progression free or overall). Six-
month PFS was the primary outcome in most of the effec-
tiveness studies. Median survival times have also been
reported.
Several studies estimated survival using the Kaplan–Meier
method, which allows estimation when there are censored observa-
tions. It should be noted, however, that survival proportions
derived from Kaplan–Meier curves are estimated survival propor-
tions at one single time point (e.g. 6 months), as opposed to a
comparison of the total survival experience of the two groups.
Hazard ratios are a more reliable means of comparing survival
between groups.
Given the poor prognosis for malignant glioma, effects on health
related quality of life (HRQL) should be considered. The EORTC
QLQ-C30 instrument was used to assess quality of life in these
studies.
More detailed discussion of factors that affect various outcome
measures and how the included studies addressed these factors
can be found in the full report (Dinnes et al, 2001).
Assessment of effectiveness – Glioblastoma Multiforme
Progression-free survival Results from the RCT (Yung et al,
2000) indicate that PFS was better in the temozolomide group,
in terms of both the proportion of patients progression-free at 6
months (13% higher) and median PFS (4 weeks longer) (see Table
2). The statistical signiﬁcance of these results was not provided.
The number needed to treat (NNT) to achieve an extra progres-
sion-free patient at 6 months was 8 (95% CI: 5, 23 calculated by
the authors).
The hazard ratio for the whole data set for PFS was 1.54 (CIs
not provided), and for median PFS was 1.47 (95% CI: 1.11, 1.95).
In the uncontrolled study, 6-month PFS was 19% (95% CI: 12,
26%) and median PFS was 9.1 weeks for the whole sample and 9.6
weeks for those who were chemotherapy-naı ¨ve (n=98) (Brada et al,
2001).
Survival The increases in overall survival demonstrated in the
RCT were not found to be signiﬁcant, although the logrank test
indicated that there may have been meaningful differences across
the groups (P=0.019). The reported nonsigniﬁcant difference in
median survival was 1.5 months (Yung et al, 2000). Median survi-
val in the uncontrolled study was 23.4 weeks (Brada et al, 2001).
Health-related quality of life Patients receiving temozolomide
in the RCT who remained progression free at 6 months showed
improvements in ﬁve of seven pre-selected quality of life domains,
although only one effect size was greater than 0.5 and only one was
statistically signiﬁcant (Osoba et al, 2000a). Patients receiving
Table 1 Included studies
Yung et al, 2000 Brada et al, 2001 Yung et al, 1999 Bower et al, 1997 Newlands et al, 1996
Histological group GBM GBM AA Mixed Mixed
Study design RCT uncont’d uncont’d uncont’d uncont’d
Number of patients 225 138 162 116 48
Inclusion criteria
Adults 518 Y Y Y Y Y
Histological conﬁrmation Y Y Y Y Y
Recurrence status 1st 1st 1st NR NR
Performance status KPS 570 KPS 570 KPS 570 WHO 43 N/A
Life expectancy 512 wks 512 wks 512 wks 512 wks N/A
Receipt of prior chemotherapy adj: 68% adj: 29% adj: 60% any: 30% any: 10%
Mixed=mixed histologies included; uncont’d=uncontrolled study; NR=not reported; KPS=Karnofsky performance status; WHO=World Health
Organisation performance status scale; wks=weeks; N/A=not applied; adj=adjuvant chemotherapy; any=chemotherapy received either as adjuvant
treatment or at previous tumour relapse.
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free at 6 months showed improvements in all seven pre-selected
domains. In this case, all seven effect sizes were less than 0.5
(usually considered small) and only three were statistically signiﬁ-
cant (Osoba et al, 2000a). In contrast, the patients receiving
procarbazine in the RCT who remained progression-free, reported
diminished HRQL in six domains, though none were statistically
signiﬁcant.
Progression of disease tended to lead to deterioration in HRQL
scores across all groups, regardless of treatment. However, in temo-
zolomide groups, there were improvements from baseline in the
weeks preceding progression.
Anaplastic astrocytoma
Survival One uncontrolled study was found with results largely
for people with AA (Yung et al, 1999). Six month PFS was better
than for those with GBM at 46%, with a median length of survival
of 23.5 weeks (Table 2). Results for those who were chemotherapy-
naı ¨ve were not signiﬁcantly better. Median survival from recur-
rence was 59 weeks for the whole sample and 50 weeks for the
chemotherapy-naı ¨ve group.
Health-related quality of life HRQL results in AA were similar
to those for GBM. Those patients who remained progression free at
6 months showed improvements in all seven pre-selected quality of
94 duplicates
Studies of temozolomide (all indications) n = 227
Abstracts screened for retrieval n = 133
Studies of effectiveness or quality of life on TMZ in
malignant glioma n = 21
Included: 7 papers
5 effectiveness of TMZ in  GBM or AA
2 HRQL
Excluded: 12 studies with < 45 subjects
               : 1 study of AO/AOA
               : 1 study available in abstract only
Excluded: 112 other indications,
pharmacokinetic studies,
reviews/commentaries
Figure 1 Flow diagram of temozolomide effectiveness search results.
Table 2 Summary of effectiveness results
6 month
PFS (%)
Study (95% CI) Survival (95% CI) Other outcomes
GBM
Yung et al (2000) TMZ 21 (13, 29) 6 month survival: 60% (51,70) median PFS: TMZ=12.4 weeks
RCT (n=225) PRO=8.32 weeks
PRO 8 (3, 14) 6 month survival: 44% (35, 53) TMZ 6 weeks median survival
advantage, NS
Brada et al (2001) 19 (12, 26) Median 23.4 weeks median PFS: 9.1 weeks
single group (n=138) 6 month survival: 46%
AA or AOA
Yung et al (1999) 46 (38, 54) Median 59 weeks median PFS: 23.5 weeks
single group (n=162)
Mixed histologies
Bower et al (1997) 22 (14, 31) Median 25.2 weeks (20, 30.4)
single group (n=116)
(results from 103 eligible)
Newlands et al (1996) In recurrent disease: 1 year
single group (n=48) survival =22% (12, 36)
TMZ=temozolomide; PRO=procardazine; NS=not statistically signiﬁcant.
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small (less than 0.5) and reached statistical signiﬁcance in only two
domains.
Mixed histologies
Limited results were available from the two studies conducted in
mixed histological groups. One study reported 6-month PFS of
22% (95% CI: 14, 31%) (Newlands et al, 1996). The other reported
a median survival of 25.2 weeks (Bower et al, 1997).
Adverse effects of temozolomide
Myelosuppression is the most serious adverse effect of temozolo-
mide and is dose limiting; however, it does not appear to be
cumulative and is relatively easily treated. Between 6 and 10% of
patients suffered grade 3 or 4 thrombocytopenia, less than 5%
suffered each of grade 3 or 4 neutropenia, leukopenia or anaemia.
A wide range of other grade 3 or 4 adverse effects were noted in
one study (Yung et al, 1999), most commonly asthenia (6%), head-
ache (6%), nausea (10%) and vomiting (6%). These occurred in
fewer patients in other studies. All studies routinely included
anti-emetics or allowed their use as needed, noting that vomiting
was generally well controlled by them.
In the RCT, the myelosuppressive effects were similar for both
drugs, but nausea, vomiting and fatigue were noted more often
in the procarbazine group (Yung et al, 2000). The number of
adverse effects is affected by the number of cycles administered
and length of treatment: over 90% of patients on temozolomide




Evidence to date, though limited, indicates that recurrent malig-
nant glioma has some response to temozolomide. This response
appears to be greater in AA than in GBM.
The main beneﬁt in patients with GBM, demonstrated in one
RCT and one relatively large uncontrolled study, is an increase
(13%) in the estimated proportion of patients remaining progres-
sion-free at 6 months and a signiﬁcant increase in median PFS
of approximately 4 weeks. However, there was no signiﬁcant over-
all survival advantage.
For patients with AA, one large uncontrolled study suggests
favourable PFS and possibly increased overall survival. The magni-
tude of any beneﬁt in AA is difﬁcult to quantify due to the lack of
a within study comparison of temozolomide with an alternative
treatment regimen.
Temozolomide appears to involve few serious adverse effects.
Vomiting appears to be well controlled by prophylactic anti-emetic
regimens. Some clinicians believe that toxicity, particularly myelo-
suppression, is more predictable with temozolomide and this has
been noted as one of the advantages of this drug over others. It
should be noted, however, that little empirical evidence is available
to support this position.
Temozolomide may appear to improve HRQL from recurrence
until at or near disease progression and may confer considerably
better quality of life than procarbazine. Given the cognitive impair-
ments associated with brain tumours these improvements may be
important in the daily functioning of patients and in their relation-
ships with family and friends.
The incidence of AA and GBM in the UK is around three to
four per 100000 (Ofﬁce for National Statistics, 2000). Current
direct costs of treating malignant glioma in the UK are about
£25 million per annum. Approximately 30% of patients have been
considered for chemotherapy in the past. If this proportion were to
be maintained, then around 600 patients per year could be eligible
to receive temozolomide at an annual incremental cost to the NHS
of about £4 million (Dinnes et al, 2001).
Assumptions, limitations and uncertainties
This review was conducted rigorously and provides a balanced
assessment of the current evidence. The search was extensive and
it is very unlikely that RCTs were missed. It is also likely that all
relevant uncontrolled studies were included, but the possibility here
of publication bias is slightly greater. The conclusions that can be
drawn from this review are however tentative and should be treated
with caution, because of limitations in the evidence.
There were problems with the validity of the studies. Uncon-
trolled studies were eligible for inclusion in the review because of
the anticipated lack of evidence from RCTs. Such studies, however,
can only provide a broad indication of the potential effect of a
treatment; they do not permit valid comparisons with alternative
treatments. The only RCT found had several problems. It was
conducted only in patients with GBM, did not use a comparator
that is common in the UK, and was not powered to detect a clini-
cally signiﬁcant difference in outcomes. Limited details of the
methods used in the trial, including methods of randomization,
were available.
The reporting of results was problematic. First, increases in
survival were presented as median rather than mean ﬁgures.
Median results may provide a distorted summary of average
increases in survival times when a treatment increases the life
expectancy of some patients by a few weeks but has little or no
impact on the survival of the patients who would otherwise live
longest. Second, although in most studies radiological data were
centrally reviewed and often by masked reviewers, there remained
scope for biased assessment of outcomes, as many of the outcome
measures used – particularly those evaluating tumour response –
were subjective. None of the studies reviewed (including the RCT)
used single or double-binding, largely due to the uncontrolled
nature of the studies. Subjective clinical assessments and patients’
self-reported quality of life may have been affected by knowledge
of the treatment.
The generalizability of the results from the included studies is
questionable, for three reasons. First, procarbazine was chosen as
the comparator in the RCT because it is administered orally and
is one of the few options available to patients who have recurrent
glioma, particularly if they have had previous nitrosourea therapy.
However, it is not commonly used alone in the UK, but instead is
often used in combination therapy (PCV), at a lower dose than in
the trial. Second, the method of recruiting subjects was not
reported in three of the four uncontrolled studies (Bower et al,
1997; Yung et al, 1999; Brada et al, 2001). This may have led to
the patients enrolled not being representative of the wider popula-
tion of patients. Moreover, the performance status and life
expectancy criteria applied in the studies will have led to the selec-
tion of patients who may have been somewhat healthier than those
who would be offered temozolomide in practice. Third, the effect
of temozolomide in patients who have undergone prior chemother-
apy regimens compared to those who are chemotherapy naı ¨ve has
yet to be established. It is plausible that prior chemotherapy should
affect patients’ response to future chemotherapy regimens, but
evidence to date is based only on analyses in both subgroups of
patients.
Need for further research
Considerable research on temozolomide is ongoing, consisting
mainly of uncontrolled studies in relatively small patient groups.
The most pressing need is for adequately powered multi-centre
RCTs that compare temozolomide for recurrent glioma with best
alternative care such as PCV. These should recruit a large propor-
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with best prognosis) and be stratiﬁed by receipt of prior
chemotherapy. Some of these research needs may be fulﬁlled by
current ongoing or planned trials, although these are not expected
to complete recruitment for several years (Dinnes et al, 2001).
CONCLUSIONS
In summary, there is some indication of beneﬁt from temozolo-
mide, but the evidence is too weak for ﬁrm conclusions to be
drawn and further large RCTs are required. The incidence of
malignant glioma is relatively low and the overall budgetary impact
for the NHS as a whole is in the order of £4 million per annum.
ADDENDUM
Since this article was submitted for publication, a further uncon-
trolled study has been published that would meet the inclusion
criteria for our review. This study evaluated temozolomide in 56
patients with recurrent glioblastoma multiforme, anaplastic astro-
cytoma or anaplastic oligodendrogliomas (Harris et al, 2001).
The results were very similar to those in the other studies identiﬁed
and would not change the overall conclusions of our review.
Median progression free survival was 26 weeks and median survival
was 48 weeks; results were substantially worse for those with glio-
blastoma multiforme in comparison to the other histologies.
ACKNOWLEDGEMENTS
This project was commissioned by the NHS HTA Programme on
behalf of NICE. The views expressed in this paper are those of
the authors, and do not necessarily reﬂect those of the Department
of Health. Thanks to Dr Pam Royle Information Scientist at
SHTAC for invaluable assistance with the literature searching.
We would also like to thank our clinical advisers, Professor Ed
Newlands, Dr Michael Brada and Dr Roy Rampling, for their input
but absolve them from any responsibility for the ﬁnal version
which remains the responsibility of the Southampton Health Tech-
nology Assessments Centre alone.
REFERENCES
Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJ, Calvert H, Colqu-
houn I, Lewis P, Brampton MH (1997) Multicentre CRC phase II trial of
temozolomide in recurrent or progressive high-grade glioma. Cancer
Chemother Pharmacol 40: 484–488
Brada M, Hoang-Xuan K, Rampling R, Dietrich P-Y, Dirix L, Macdonald D,
Heimans J, Zonnenberg B, Bravo-Marques J, Henriksson R, Stupp R, Yue
N, Bruner J, Dugan M, Rao S, Zaknoen S (2001) Multicenter phase II trial
of temozolomide in patients with glioblastoma multiforme at ﬁrst relapse.
Ann Oncol 12: 259–266
Dinnes J, Cave CB, Huang S, Major K, Milne RM (2001) The effectiveness
and cost-effectiveness of temozolomide for the treatment of recurrent
malignant glioma. Health Technol Assess 5(13): 1–73
Galanis E, Buckner J (2000) Chemotherapy for high-grade gliomas. Br J
Cancer 82: 1371–1380
Harris MT, Rosenthal MA, Ashley DL, Cher L (2001) An Australian experi-
ence with temozolomide for the treatment of recurrent high grade gliomas.
J Clin Neurosci 8: 325–327
Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan D,
McQuay HJ (1996) Assessing the quality of reports of randomized clinical
trials: is blinding necessary? Control Clin Trials 17: 1–12
Newlands ES, O’Reilly SM, Glaser MG, Bower M, Evans H, Brock C, Bramp-
ton MH, Colquhoun I, Lewis P, Rice-Edwards JM, Illingworth RD,
Richards PG (1996) The Charing Cross Hospital experience with temozo-
lomide in patients with gliomas. Eur J Cancer Part A 32: 2236–2241
Ofﬁce for National Statistics (2000) Health Statistics Quarterly (Autumn)
London: The Stationery Ofﬁce National Statistics
Osoba D, Brada M, Yung WK, Prados M (2000a) Health-related quality of life
in patients treated with temozolomide versus procarbazine for recurrent
glioblastoma multiforme. J Clin Oncol 18: 1481–1491
Osoba D, Brada M, Yung WKA, Prados M (2000b) Health-related quality of
life in patients with anaplastic astrocytoma during treatment with temozo-
lomide. Eur J Cancer 36: 1788–1795
Rampling R (2000) CRC CancerStats: Brain. CRC CancerStats
Spitzer WO, Lawrence V, Dales R, Hill G, Archer MC, Clark P, Abenheim L,
Hardy J, Sampalis J, Pinfold SP, Morgan PP (1990) Links between passive
smoking and disease; A best-evidence synthesis. Clin Invest Med 13: 17–42
The European Agency for the Evaluation of Medicinal Products (1999)
Committee for Proprietary Medicinal Products European Public Assess-
ment Report (EPAR): Temodal.
Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin
VA, Yung WKA (1999) Outcomes and prognostic factors in recurrent glio-
ma patients enrolled onto phase II clinical trials. J Clin Oncol 17: 2572–
2578
Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M,
Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick
NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D,
Zaknoen S, Levin VA (2000) A phase II study of temozolomide vs. procar-
bazine in patients with glioblastoma multiforme at ﬁrst relapse. Br J Cancer
83: 588–593
Yung WKA, Prados MD, Yaya TR, Rosenfeld SS, Brada M, Friedman HS,
Albright R, Olson J, Chang SM, O’Neill AM, Friedman AH, Bruner J,
Yue N, Dugan M, Zaknoen S, Levin VA (1999) Multicenter phase II trial
of temozolomide in patients with anaplastic astrocytoma or anaplastic
oligoastrocytoma at ﬁrst relapse. J Clin Oncol 17: 2762–2771
Temozolomide for recurrent malignant glioma
J Dinnes et al
505
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(4), 501–505